Moreover, newly discovered small molecules inhibitor of FOXO1 and FOXM1 have shown efficacy in preclinical cancer models [123–125], demonstrating the feasibility of targeting FOX transcription factors in vivo as well. This evidence concerns the gene FOXO1 and cancer.